Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer

Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer is a phase 2, randomised interventional study registered as NCT07469306 by Fujian Cancer Hospital, with a registry enrolment figure of 130 participants, started 2026-08-10 and due to reach its primary completion in 2027-08-10. Interventions recorded: Modified Short-course radiotherapy; Long-course radiotherapy; Oxaliplatin; Capecitabine; Tislelizumab; Capecitabine; Tislelizumab. Conditions listed: Locally Advanced Rectal Cancer. Primary outcome: Complete Response (CR) Rate. Colorectal eligibility wording from the registry: "* Pathologically confirmed rectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.